Bavdegalutamide, a proteolysis-targeting chimera (PROTAC) degrader of the androgen receptor (AR), shows promise in prostate cancer treatment [37], while TAM-IN-2, a TAM receptor inhibitor, effectively blocks Gas6-induced AXL activation and suppresses lung cancer progression. The gene discussed is GAS6; the disease is prostate cancer.